Evidence map›Paper›PMID 37055488›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2023

Robust aversive effects of trace amine-associated receptor 1 activation in mice.

Shkelzen Shabani, Sydney Houlton, Bikalpa Ghimire, Derek Tonello, Cheryl Reed, Harue Baba, Sara Aldrich, Tamara J Phillips

Open access · greenAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Shkelzen ShabaniDepartment of Biomedical Sciences, Grand Valley State University, Allendale, MI, USA.
Sydney HoultonDepartment of Biology, Minot State University, Minot, ND, USA.
Bikalpa GhimireDepartment of Biology, Minot State University, Minot, ND, USA.
Derek TonelloDepartment of Biomedical Sciences, Grand Valley State University, Allendale, MI, USA.
Cheryl ReedDepartment of Behavioral Neuroscience and Methamphetamine Abuse Research Center, Oregon Health & Science University, Portland, OR, USA.
Harue BabaDepartment of Behavioral Neuroscience and Methamphetamine Abuse Research Center, Oregon Health & Science University, Portland, OR, USA.
Sara AldrichDepartment of Behavioral Neuroscience and Methamphetamine Abuse Research Center, Oregon Health & Science University, Portland, OR, USA.
Tamara J PhillipsDepartment of Behavioral Neuroscience and Methamphetamine Abuse Research Center, Oregon Health & Science University, Portland, OR, USA. phillipt@ohsu.edu.ORCID 0000-0002-7350-6323
Oregon Health & Science University · USGrand Valley State University · USMinot State University · US

Funding

Research CoresP20GM103442 · NIGMS · UNIVERSITY OF NORTH DAKOTA · PI Donald A. Sens · 2012 to 2026
$53.0M
Traditional Service Core [Translational Service Core (TSC)]P50DA018165 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI PHILLIPS, TAMARA J. · 2006 to 2016
$13.0M
Genetic Risk for Methamphetamine AbuseU01DA041579 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI PHILLIPS, TAMARA J. · 2016 to 2020
$2.1M
Genetic Factors Underlying Risk for Methamphetamine Intake and Associated TraitsR01DA046081 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI PHILLIPS, TAMARA J. · 2018 to 2022
$1.7M
Genetic basis of methamphetamine intakeI01BX002106 · VA · PORTLAND VA MEDICAL CENTER · PI PHILLIPS, TAMARA J. · 2014 to 2022
–
BLRD VA I01 BX002106BLRD VA IK6 BX006342NIDA NIH HHS P50 DA018165NIDA NIH HHS R01 DA046081NIDA NIH HHS U01 DA041579NIGMS NIH HHS P20 GM103442ORD VA 15F-RCS-009
6 · The paper itself

Abstract

Drugs that stimulate the trace amine-associated receptor 1 (TAAR1) are under clinical investigation as treatments for several neuropsychiatric disorders. Previous studies in a genetic mouse model of voluntary methamphetamine intake identified TAAR1, expressed by the Taar1 gene, as a critical mediator of aversive methamphetamine effects. Methamphetamine is a TAAR1 agonist, but also has actions at monoamine transporters. Whether exclusive activation of TAAR1 has aversive effects was not known at the time we conducted our studies. Mice were tested for aversive effects of the selective TAAR1 agonist, RO5256390, using taste and place conditioning procedures. Hypothermic and locomotor effects were also examined, based on prior evidence of TAAR1 mediation. Male and female mice of several genetic models were used, including lines selectively bred for high and low methamphetamine drinking, a knock-in line in which a mutant form of Taar1 that codes for a non-functional TAAR1 was replaced by the reference Taar1 allele that codes for functional TAAR1, and their matched control line. RO5256390 had robust aversive, hypothermic and locomotor suppressing effects that were found only in mice with functional TAAR1. Knock-in of the reference Taar1 allele rescued these phenotypes in a genetic model that normally lacks TAAR1 function. Our study provides important data on TAAR1 function in aversive, locomotor, and thermoregulatory effects that are important to consider when developing TAAR1 agonists as therapeutic drugs. Because other drugs can have similar consequences, potential additive effects should be carefully considered as these treatment agents are being developed.

Indexed as

MethamphetamineAnimalsFemaleMaleMiceReceptors, G-Protein-CoupledTrace Amine-Associated ReceptorsMethamphetamineReceptors, G-Protein-CoupledTrace Amine-Associated Receptors

Identifiers

PMID37055488
PMCPMC10425385
OpenAlexW4365447318

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.